<SEC-DOCUMENT>0001104659-21-062456.txt : 20210506
<SEC-HEADER>0001104659-21-062456.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506164024
ACCESSION NUMBER:		0001104659-21-062456
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210430
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inotiv, Inc.
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		21898536

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOANALYTICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19970918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2115487d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
April 30, 2021&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 14pt">INOTIV,
    INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Registrant's telephone number, including area code:
(765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 28%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Ticker symbol(s)</FONT></TD>
    <TD STYLE="width: 35%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NOTV</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01 Entry into a Material Definitive
Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
in Item 2.03 regarding the Credit Agreement is incorporated by reference into this Item 1.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.01 Completion of Acquisition or Disposition
of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed, on
April 13, 2021, Inotiv, Inc., an Indiana corporation (the &ldquo;<U>Company</U>&rdquo;), and Inotiv &ndash; Boulder HTL, LLC, a wholly
owned subsidiary of the Company (the &ldquo;<U>Purchaser</U>&rdquo;), entered into an Asset Purchase Agreement (the &ldquo;<U>Purchase
Agreement</U>&rdquo;) with HistoTox Labs, Inc., a Colorado corporation (the &ldquo;<U>Seller</U>&rdquo;), and its stockholder. On April
30, 2021, the Company closed the transactions contemplated by the Purchase Agreement, indirectly acquiring (the &ldquo;<U>Acquisition</U>&rdquo;)
substantially all of the assets of Seller used or useful by Seller in connection with Seller's business of non-clinical consulting, laboratory
and strategic support services and products related to routine and specialized histology, immunohistology, histopathology and image analysis/digital
pathology. Consideration for the Acquisition consisted of $22.0 million in cash, subject to certain adjustments and inclusive of a $1.65
million escrow for purposes of securing any amounts payable by the selling parties on account of indemnification obligations and other
amounts payable under the Purchase Agreement. In addition, the Purchaser assumed certain specified liabilities of the Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also as previously disclosed,
on April 15, 2021, the Company, entered into an Agreement and Plan of Merger (the &ldquo;<U>Merger Agreement</U>&rdquo;) with Rock Mergeco,
Inc., a Colorado corporation and a wholly-owned subsidiary of the Company, Inotiv Boulder, LLC, an Indiana limited liability company and
a wholly-owned subsidiary of the Company (&ldquo;<U>Inotiv Boulder</U>&rdquo;), Bolder BioPATH, Inc., a Colorado corporation (&ldquo;<U>Bolder
BioPATH</U>&rdquo;), and the holders of all of the outstanding common shares of Bolder BioPATH (the &ldquo;<U>Selling Shareholders</U>&rdquo;).
On April 30, 2021, the Company closed (the &ldquo;<U>Closing</U>&rdquo;) the transactions contemplated by the Merger Agreement and the
merger under the Merger Agreement was consummated on May 3, 2021 (the &ldquo;<U>Merger</U>&rdquo;). Following the Merger, Inotiv Boulder,
as the surviving wholly owned subsidiary of the Company, serves as a contract pharmacology and pathology company specializing in in vivo
models of rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other autoimmune and inflammation models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Closing, the Company
paid consideration to the Selling Shareholders, consisting of (i) $18.5 million in cash, subject to customary purchase price adjustments
and inclusive of $1.25 million being held in escrow for purposes of securing any amounts payable by the selling parties on account of
indemnification obligations, purchase price adjustments, and other amounts payable under the Merger Agreement, (ii) 1,588,235 of the Company&rsquo;s
common shares and (iii) seller notes in an aggregate principal amount of $1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.03 Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of the Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) General Description of Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2021, the Company
entered into an Amended and Restated Credit Agreement (the &ldquo;<U>Credit Agreement</U>&rdquo;) with First Internet Bank of Indiana
(&ldquo;<U>FIB</U>&rdquo;) to, among other things, secure additional debt financing in order to fund portions of the consideration for
the Acquisition and the Merger, respectively. The Credit Agreement includes eleven term loans (the &ldquo;<U>Term Loans</U>&rdquo; ),
an equipment draw loan (the &ldquo;<U>Equipment Loan</U>&rdquo;), and a revolving line of credit (the &ldquo;<U>Revolving Facility</U>&rdquo;).
The terms of each such loans are set forth below. The obligations of the Company under the Credit Agreement are secured by all of the
assets of the Company and are guaranteed by each of its subsidiaries and secured by the assets thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included in the Credit Agreement
is a requirement that the Company maintain certain financial covenants, including maintaining a senior funded debt to adjusted EBITDA
ratio (as defined in the Credit Agreement) of not greater than (i) 5.25 to 1.00 as of the date of the Credit Agreement and as of June
30, 2021, (ii) 4.75 to 1.00 as of September 30, 2021, (iii) 4.50 to 1.00 as of December 31, 2021, (iv) 4.25 to 1.00 as of March 31, 2022,
(v) 4.00 to 1.00 as of June 30, 2022, and (vi) 3.50 to 1.00 as of September 30, 2022 and as of each fiscal quarter end thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also included in the Credit
Agreement is a requirement that the Company maintain a fixed charge coverage ratio (as defined in the Credit Agreement) of not less than
(i) 1.20 to 1.00, commencing as of September 30, 2021, and continuing as of each fiscal quarter end thereafter up to and including June
30, 2022, and (ii) 1.25 to 1.00 as of September 30, 2022 and as of each fiscal quarter end thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Terms of the Equipment Loan<B>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may borrower under
the Equipment Loan on or before April 30, 2022 in the aggregate principal amount of up to $3.0 million (the &ldquo;<U>Equipment Loan Commitment</U>&rdquo;).
The Equipment Loan Commitment shall automatically terminate upon the earlier of (x) any funding of the maximum amount of the Equipment
Loan Commitment and (y) at 5:00 p.m., Indianapolis time, April 30, 2022. Until April 30, 2022, the Company must pay interest on the amount
outstanding under the Equipment Loan at a fixed annual rate of 4.00%. On April 30, 2022, all amounts outstanding under the Equipment Loan
shall be converted to a term loan and repaid monthly in installments of principal based on a five (5) year amortization schedule together
with the interest that shall accrue thereon. A final installment representing the entire unpaid principal of the Equipment Loan, and all
accrued and unpaid interest thereon and all fees and charges in connection therewith, shall be due and payable on April 30, 2027. Advances
under the Equipment Loan shall be used to fund equipment needs of the Company as approved by FIB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Terms of the Revolving Facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Revolving Facility provides
a line of credit for up to $5.0 million, which the Company may borrow from time to time, subject to the terms of the Credit Agreement,
including as may be limited by the amount of the Company&rsquo;s outstanding eligible receivables. The Revolving Facility requires monthly
accrued and unpaid interest payments only until maturity at a floating per annum rate equal to the greater of (a) 4%, or (b) the sum of
the Prime Rate plus Zero Basis Points (0.0%), which rate shall change concurrently with the Prime Rate. The Company did not have an outstanding
balance on the Revolving Facility as of the effective date of the Credit Agreement. Advances under the Revolving Facility shall be used
for general working capital purposes of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Terms of the Term Loans:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Loan Name</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Principal Amount as of date of Credit Agreement</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Annual Interest Rate</B></FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Monthly Payment Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(000)</B></P></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maturity Date</B></FONT></TD>
    <TD STYLE="width: 32%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Use of Proceeds</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$3.980 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">5.20%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$36</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">March 28, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded expansion of building on real property in Mount Vernon, IN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$3.571 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">5.06%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$78</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">July 2, 2023</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded a portion of the cash consideration for the Seventh Wave Laboratories acquisition</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$1.076 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">5.20%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$32</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">March 28, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded equipment needs associated with expansion of real property in Mount Vernon, IN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$1.001 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">4.63%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$20</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">November 1, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded the cash consideration for the Smithers Avanza acquisition</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$810 thousand</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">4.00%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">June 30, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded certain capital expenditures</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$2.865 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">4.25%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$56</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">December 31, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded certain capital expenditures</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$1.263 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">4.00%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$28</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">June 1, 2025</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Financed aspects of the Pre-Clinical Research Services and related real property acquisitions</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$1.853 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">4.00%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">December 1, 2024</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Financed aspects of the Pre-Clinical Research Services and related real property acquisitions</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 9</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$10.000 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">3.85%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$184*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">April 30, 2026</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded a portion of the cash consideration of the Merger</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 10</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$5.000 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">3.85%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$92*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">April 30, 2026</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Funded a portion of the cash consideration of the Acquisition</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Term Loan 11</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$3.622 million</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">3.99%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$33</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">June 23, 2022</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Refinanced debt with The Huntington Bank for general business purposes</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*See Mandatory Prepayments information below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) Mandatory Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing with the fiscal
year ending September 30, 2021 and for each fiscal year thereafter until the Term Loan 9 and/or Term Loan 10, in each case, are paid in
full, the Company shall prepay Term Loan 9 and Term Loan 10 on a pro rata basis on the following January 31<SUP>st</SUP>, in an amount
equal to 50% of the excess cash flow of the Company (as defined in the Credit Agreement) for such fiscal year (in each case, an &ldquo;<U>Excess
Cash Flow Payment</U>&rdquo;), provided that for the fiscal year ending September 30, 2021 the Excess Cash Flow Payment, if any, shall
be calculated only for the period from April 30, 2021 through September 30, 2021. Excess Cash Flow shall be calculated for each fiscal
year based on (a) the Company&rsquo;s adjusted EBITDA (as defined in the Credit Agreement), minus (b) cash interest expense, minus (c)
cash taxes paid or cash distributions made for payment of taxes, minus (d) principal payments paid in respect of long-term indebtedness
(excluding any principal reduction on Term Loan 9 or Term Loan 10, in each case, with respect to Excess Cash Flow and excluding principal
payments on the Revolving Facility), minus (e) capital expenditures not funded by advances under the Equipment Loan as specified under
the Credit Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon an event of default,
which includes certain customary events such as, among other things, a failure to make required payments when due, a failure to comply
with covenants, certain bankruptcy and insolvency events, and defaults under other material indebtedness, FIB may cease advancing funds,
increase the interest rate on outstanding balances, accelerate amounts outstanding, terminate the agreement and foreclose on all collateral.
The Company has also obtained a life insurance policy in an amount not less than $5.0 million for its President and Chief Executive Officer
and provided FIB an assignment of such life insurance policy as collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3.02 Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
the Company issued 1,588,235 of the Company&rsquo;s common shares to the Selling Shareholders at the Closing. The shares were issued in
reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;),
provided by Section 4(a)(2) of the Securities Act as sales by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2021, the Company
issued a press release with respect to the Acquisition and the Merger, a copy of which is attached to this Current Report on Form 8-K
as Exhibit 99.3 and is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or incorporated by reference in any filing
under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Financial Statements of Businesses or Funds
Acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>The audited financial statements of HistoTox Labs, Inc. as of and for the fiscal year ended December 31, 2020, together with the notes
thereto and the report of the independent auditor thereon, are filed as Exhibit 99.3 to the Company&rsquo;s Current Report on Form 8-K
filed April 20, 2021 and are incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The audited financial statements of Bolder BioPATH, Inc. as of and for the fiscal years ended December
31, 2019 and 2020, together with the notes thereto and the report of the independent auditor thereon, are filed as Exhibit 99.2 to the
Company&rsquo;s Current Report on Form 8-K filed April 20, 2021 and are incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Pro Forma Financial Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company intends to file
the pro forma financial information required by Item 9.01(b) as part of an amendment to this Current Report on Form 8-K not later than
71 calendar days after the date that this Current Report on Form 8-K is required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 6%"><A HREF="https://www.sec.gov/Archives/edgar/data/720154/000110465921052631/tm2113490d1_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 93%"><A HREF="https://www.sec.gov/Archives/edgar/data/720154/000110465921052631/tm2113490d1_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited financial statements of HistoTox Labs, Inc. as of and for the fiscal year ended December 31, 2020, together with the notes thereto and the report of the independent auditor thereon (incorporated by reference to Exhibit 99.3 to the Company&rsquo;s Form 8-K filed April 20, 2021).</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/720154/000110465921052631/tm2113490d1_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/720154/000110465921052631/tm2113490d1_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited financial statements of Bolder BioPATH, Inc. as of and for the fiscal years ended December 31, 2019 and 2020, together with the notes thereto and the report of the independent auditor thereon (incorporated by reference to Exhibit 99.2 to the Company&rsquo;s Form 8-K filed April 20, 2021).</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="tm2115487d1_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2115487d1_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated April 30, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Inotiv, Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: May 6, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Beth A. Taylor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Vice President - Finance</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>2
<FILENAME>tm2115487d1_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>Inotiv, Inc. Announces Debt Financing
and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WEST LAFAYETTE, IN</B>, April 30, 2021 &ndash;
<B>Inotiv, Inc. (NASDAQ:NOTV) (the &ldquo;Company&rdquo;, &ldquo;We&rdquo;, &ldquo;Our&rdquo; or &ldquo;Inotiv&rdquo;)</B>, a leading
contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that
the Company has secured $28.0 million in debt financing from First Internet Bank of Indiana and completed the previously-announced acquisition
of substantially all of the assets of HistoTox Labs, Inc. (&ldquo;HistoTox Labs&rdquo;) and the acquisition by merger of Bolder BioPATH,
Inc. (&ldquo;Bolder BioPATH&rdquo;), effective April 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate consideration paid for substantially
all of the assets of HistoTox Labs consisted of $22.0 million in cash and the assumption of certain specified liabilities of the seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate consideration paid to the shareholders
of Bolder BioPATH in the merger consisted of $18.5 million in cash, 1,588,235 Inotiv common shares, and $1.5 million in subordinated notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;These strategic acquisitions expand our
nonclinical pharmacology and histopathology services and augment and extend the effective range of our services from early discovery through
preclinical development,&rdquo; said Robert Leasure, Jr., Inotiv&rsquo;s President and Chief Executive Officer.&nbsp;&ldquo;This will
increase the breadth of discovery pharmacology models that we can offer clients pursuing traditional oral small molecule therapies to
next generation injectables and gene therapies. By combining these acquisitions with our planned expansion and investments, we are positioned
to offer comprehensive laboratory solutions in DMPK and cell &amp; molecular biology, immunohistochemistry and histopathology to clients
pursuing preclinical drug safety and efficacy programs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Current Report on Form 8-K containing further
details regarding the debt financing will be filed by Inotiv and made available on the U.S. Securities and Exchange Commission&rsquo;s
EDGAR website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inotiv, Inc. is a pharmaceutical development
company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading
drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its
clients&rsquo; discovery and development objectives for improved decision-making and accelerated goal attainment. The
Company&rsquo;s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit <FONT STYLE="color: Blue"><U>inotivco.com</U></FONT>
for more information about the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release may contain forward-looking statements
that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and
demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the
impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken
by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various
other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><B>Company Contact</B></TD>
    <TD STYLE="width: 16%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: justify"><B>Investor Relations</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Inotiv, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">The Equity Group Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Beth A. Taylor, Chief Financial Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Kalle Ahl, CFA</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(765) 497-8381</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(212) 836-9614</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Blue"><U>btaylor@inotivco.com</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Blue"><U>kahl@equityny.com</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Devin Sullivan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(212) 836-9608</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Blue"><U>dsullivan@equityny.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& (H# 2(  A$! Q$!_\0
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B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G RX# 2(  A$! Q$!_\0
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MM7T-JKSD[GMI@A$)^:97*KQVX&?2MC^VK/\ Z:_]^F_PH_MJS_Z:_P#?IO\
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MI_*S UN5I]4CFA,I!CB,&T/E\L23'C@''7=5EFU'_A)X9)[>1(V654*R!E"
M#!P._.??/M6M_;5G_P!-?^_3?X4?VU9_]-?^_3?X4?6*7\R#V-3^5F1X>>*Q
MDFC5_.@VQC[2870F0DC80<Y/O[\U'%+>QZU<S:C;3QJUG(7V2@A5!XVX[XX]
M<DFMO^VK/_IK_P!^F_PH_MJS_P"FO_?IO\*/K%+^9![&I_*S L_.EL+E=/1G
MCF=3);I*084QR S?Q-WQTJO<-=OI.F"X#QPK:DA&1I!)*,;0=I&,CIZ5T_\
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M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HK/\
M[:LO67_ORW^%']M67K+_ -^6_P */K%+^9!["I_*S0HK/_MJR]9?^_+?X4?V
MU9>LO_?EO\*/K%+^9!["I_*S0HK/_MJR]9?^_+?X4?VU9>LO_?EO\*/K%+^9
M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HK/\
M[:LO67_ORW^%']M67K+_ -^6_P */K%+^9!["I_*S0HK/_MJR]9?^_+?X4?V
MU9>LO_?EO\*/K%+^9!["I_*S0HK/_MJR]9?^_+?X4?VU9>LO_?EO\*/K%+^9
M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HHHK8
MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
